BofA Securities raises argenx stock price target to $880 on strong Vyvgart sales

BofA Securities raised its price target for argenx SE to $880, maintaining a Buy rating, after the biotech company reported second-quarter Vyvgart revenues of $949 million, significantly exceeding analyst estimates and driven by strong global demand and the successful launch of its pre-filled syringe option. This robust performance, with Vyvgart approaching $1 billion in quarterly sales, positions argenx as a top pick for 2025, underpinned by a strong balance sheet. However, the company faces regulatory scrutiny as the FDA evaluates potential severe risks associated with its Vyvgart Hytrulo formulation for CIDP, which could introduce uncertainty despite other pipeline advancements.

Analysis

Argenx SE (ARGX) demonstrated significant commercial momentum, reporting second-quarter Vyvgart revenues of $949 million, which represents 20% quarter-over-quarter growth and substantially exceeds both BofA's estimate of $885 million and consensus expectations of $863 million. This robust performance, part of an 82% year-over-year revenue growth trend, was fueled by strong global demand and the successful April launch of a pre-filled syringe option that drove a record number of new patient starts and expanded the prescriber base. Consequently, analyst sentiment is highly positive, with BofA Securities raising its price target to $880 and naming argenx a top pick for 2025, while Morgan Stanley initiated coverage with an Overweight rating. However, this bullish operational outlook is tempered by a material regulatory headwind. The FDA is currently evaluating a potential serious risk associated with Vyvgart Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a key indication for future growth. This investigation introduces significant uncertainty and a potential negative catalyst that could disrupt the product's expansion. While the company's strong balance sheet, minimal debt, and an advancing pipeline, evidenced by ARGX-119 entering late-stage development, provide a solid fundamental underpinning, the pending FDA decision remains the most critical near-term variable for the stock's trajectory.

Key Decisions for Investors

• Investors should weigh the strong commercial execution and upward revenue revisions for Vyvgart against the significant regulatory risk posed by the FDA's safety evaluation of the Vyvgart Hytrulo formulation for CIDP.
• Closely monitor all communications from the company and the FDA regarding the CIDP safety review, as any definitive regulatory action will be a major catalyst for the stock.
• Consider the company's strong underlying financials and pipeline depth, including the late-stage ARGX-119 asset, as potential mitigating factors that could provide long-term value independent of the near-term regulatory outcome for Hytrulo.